Physician profile
Aref Obagi
NPI 1154716256
$13,196.28
in general payments reported to CMS, 2019-2025
24 companies · $332 in 2025
The $332 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $56.64 · 2021: $425 · 2022: $1,904 · 2023: $7,658 · 2024: $2,357 · 2025: $332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $6,485 · Food and Beverage: $3,861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $6,485.34 |
| Food and Beverage | $3,861.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $6,150.93 | 2019-2025 | Optis, Xact, Perclose Prostyle |
| Boston Scientific Corporation | $2,473.96 | 2019-2023 | Versacross Access Solution, Eluvia, Ranger |
| Penumbra, INC. | $2,260.22 | 2023 | Indigo System |
| Cardiovascular Systems INC. | $915.35 | 2019-2023 | Diamondback Coronary |
| Abiomed | $377.63 | 2023-2024 | Impella |
| Teleflex LLC | $178.29 | 2025 | Guideliner |
| Edwards Lifesciences Corporation | $176.05 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $105.84 | 2021-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $97.68 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $84.82 | 2023 | Xarelto |
| W. L. Gore & Associates, INC. | $62.45 | 2022 | |
| Inari Medical, INC. | $42.68 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Novo Nordisk INC | $41.93 | 2024 | Ozempic, Rybelsus |
| Intuitive Surgical, INC. | $40.45 | 2025 | |
| Pfizer INC. | $28.64 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $28.34 | 2025 | |
| Akcea Therapeutics, INC. | $19.79 | 2020 | |
| Inspire Medical Systems, INC. | $19.14 | 2025 | Inspire |
| Surmodics, INC. | $18.40 | 2022 | |
| Saranas, INC. | $15.42 | 2022 | |
| Merck Sharp & Dohme LLC | $14.97 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.93 | 2019 | |
| Amgen INC. | $14.58 | 2021 | |
| Angiodynamics, INC. | $13.79 | 2023 | Alphavac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aref Obagi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.